The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials.

In a notice published on the US government’s daily journal the Federal Register, the DEA said the increase in production applied specifically to schedule I substances such as psilocybin, psilocin, cannabis and cannabis extracts.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us